This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana Gains on Strong Membership Base and Sound Cash Reserves
by Zacks Equity Research
HUM benefits from a cost-effective health plan suite, continued expansion endeavors and a strong 2025 business outlook.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Humana's CenterWell Launches Gladstone Walmart Location for Seniors
by Zacks Equity Research
The easy accessibility for patients will give HUM a competitive edge over other senior-focused healthcare providers.
Is UnitedHealth Stock Still a Buy Despite Its Premium Price Tag?
by Kaibalya Pravo Dey
UNH is making significant investments in AI and digital tools to enhance consumer experiences and streamline healthcare processes.
Humana & Icon Enhance Senior Healthcare With Integrated Specialty Care
by Zacks Equity Research
HUM's CenterWell and Conviva partner with Icon Health, improving musculoskeletal care access for seniors.
Elevance Trades at a Bargain: Is it a Good Time to Buy ELV Stock?
by Kaibalya Pravo Dey
With a strengthening commercial business, ELV is seeing steady membership growth.
Humana (HUM) Down 4.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Analyst Reports for UnitedHealth, SAP & Toyota Motor
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc. (UNH), SAP SE (SAP) and Toyota Motor Corp. (TM), as well as a micro-cap stock Better Choice Company Inc. (BTTR).
Markets Await Consumer Sentiment Data
by Zacks Equity Research
Markets Await Consumer Sentiment Data
Pre-Market Dow Sinks on UNH Report; Econ Reports After the Open
by Mark Vickery
The DOJ is bringing a civil case against UnitedHealthcare (UNH) -- the largest healthcare company in the world.
UnitedHealth Pulls Back 11% in 3 Months: Think Twice Before Buying
by Kaibalya Pravo Dey
While UNH is pushing for a more efficient and cost-effective healthcare system, ongoing regulatory uncertainty and mounting cost pressures could keep the stock under check.
Humana Incurs Wider Y/Y Loss in Q4 on Decline in Membership
by Zacks Equity Research
HUM's fourth-quarter results suffer a blow due to a membership decline in Medicare stand-alone PDP, partly offset by a strong Primary Care business. It currently expects 2025 adjusted EPS to be around $16.25.
Humana (HUM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Humana (HUM) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Humana (HUM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 4.42% and 1.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Lower Commercial Premiums Hurt Humana's Q4 Earnings?
by Zacks Equity Research
HUM's Q4 results are likely to suffer a blow due to escalating operating costs, partly offset by membership growth in the Individual and Group Medicare Advantage business lines.
Countdown to Humana (HUM) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Humana (HUM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Molina (MOH) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of -13.08% and 0.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Humana (HUM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Amgen, Cencora, Humana and Ardent Health
by Zacks Equity Research
Amgen, Cencora, Humana and Ardent Health are included in this Analyst Blog.
4 Healthcare Stocks Poised to Crush Q4 Earnings Estimates
by Kaibalya Pravo Dey
Rising patient volumes, technological advancements, rate hikes and other factors are likely to have benefited healthcare players during Q4. Companies like AMGN, COR, HUM and ARDT are likely to outperform.
Humana (HUM) Soars 3.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Humana (HUM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Is UnitedHealth a Buy After Q4 Domestic Commercial Membership Growth?
by Kaibalya Pravo Dey
UNH's Optum Health is expected to serve about 5.4 million value-based care patients in 2025.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Will Humana (HUM) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Humana (HUM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.